MX382608B - Tratamiento del prurito urémico. - Google Patents

Tratamiento del prurito urémico.

Info

Publication number
MX382608B
MX382608B MX2018011379A MX2018011379A MX382608B MX 382608 B MX382608 B MX 382608B MX 2018011379 A MX2018011379 A MX 2018011379A MX 2018011379 A MX2018011379 A MX 2018011379A MX 382608 B MX382608 B MX 382608B
Authority
MX
Mexico
Prior art keywords
treatment
uremic pruritus
pruritus
uremic
patient
Prior art date
Application number
MX2018011379A
Other languages
English (en)
Spanish (es)
Other versions
MX2018011379A (es
Inventor
Amale Hawi
Jennifer Good
Thomas Sciascia
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2018011379A publication Critical patent/MX2018011379A/es
Publication of MX382608B publication Critical patent/MX382608B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2018011379A 2016-03-21 2017-03-21 Tratamiento del prurito urémico. MX382608B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311134P 2016-03-21 2016-03-21
US201662412584P 2016-10-25 2016-10-25
PCT/US2017/023398 WO2017165409A1 (en) 2016-03-21 2017-03-21 Treatment of uremic pruritus

Publications (2)

Publication Number Publication Date
MX2018011379A MX2018011379A (es) 2019-06-13
MX382608B true MX382608B (es) 2025-03-13

Family

ID=59899743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011379A MX382608B (es) 2016-03-21 2017-03-21 Tratamiento del prurito urémico.

Country Status (11)

Country Link
US (1) US20180008592A1 (2)
EP (1) EP3432871B1 (2)
JP (2) JP2019509309A (2)
KR (1) KR20180120756A (2)
CN (1) CN109310656A (2)
AU (1) AU2017238051B9 (2)
BR (1) BR112018069174A2 (2)
CA (1) CA3017374A1 (2)
ES (1) ES2970294T3 (2)
MX (1) MX382608B (2)
WO (1) WO2017165409A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019301134A1 (en) * 2018-07-11 2021-01-21 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
KR20220127849A (ko) 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법
WO2021222886A1 (en) * 2020-05-01 2021-11-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to treat polycystic kidney disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236630T3 (es) * 1996-11-25 2005-07-16 Toray Industries, Inc. Agente antipruritico.
US20090093509A1 (en) * 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
US8686040B2 (en) * 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
ES2984559T3 (es) * 2012-12-14 2024-10-29 Trevi Therapeutics Inc Métodos de tratamiento del prurito
MX2016016404A (es) * 2014-06-13 2017-11-30 Trevi Therapeutics Inc Metodos para el tratamiento del prurito.

Also Published As

Publication number Publication date
KR20180120756A (ko) 2018-11-06
AU2017238051A1 (en) 2018-10-04
AU2017238051B2 (en) 2022-10-06
CA3017374A1 (en) 2017-09-28
EP3432871B1 (en) 2023-11-15
MX2018011379A (es) 2019-06-13
US20180008592A1 (en) 2018-01-11
EP3432871A4 (en) 2019-10-30
JP2022081640A (ja) 2022-05-31
EP3432871A1 (en) 2019-01-30
WO2017165409A1 (en) 2017-09-28
BR112018069174A2 (pt) 2019-01-29
AU2017238051B9 (en) 2022-11-03
ES2970294T3 (es) 2024-05-27
CN109310656A (zh) 2019-02-05
JP2019509309A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
PH12015502075B1 (en) Treatment of cataplexy
MX384240B (es) Bacterias probioticas recombinantes.
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MY194341A (en) Method of treating a brain tumor
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
EA201791110A1 (ru) Сублингвальное введение рилузола
PH12016502150A1 (en) Method for treating renal cell carcimona
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
JOP20190056B1 (ar) مركبات للاستخدام في علاج القصور الكلوي الحاد
MX2017000306A (es) Metodos para tratar hipotension.
TW201613587A (en) Medical treatments based on anamorelin
MX2018011379A (es) Tratamiento del prurito uremico.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
MX376191B (es) Composicion hiperosmolar de acido hialuronico.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX2016002307A (es) Tratamiento para el cancer.
EA201690446A1 (ru) Лечение множественной миеломы
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
MX2017013669A (es) Composiciones para el tramiento del cancer.
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии